Immunotherapy in relapsed mesothelioma

Immunotherapy. 2018 Feb;10(2):77-80. doi: 10.2217/imt-2017-0144.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Asbestos / adverse effects*
  • Clinical Trials as Topic
  • Costimulatory and Inhibitory T-Cell Receptors / immunology
  • Humans
  • Immunotherapy / methods*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Mesothelioma / mortality
  • Mesothelioma / therapy*
  • Occupational Diseases / immunology
  • Occupational Diseases / therapy*
  • Pleural Neoplasms / immunology
  • Pleural Neoplasms / mortality
  • Pleural Neoplasms / therapy*
  • Recurrence
  • Survival Analysis
  • Vascular Endothelial Growth Factor A / immunology

Substances

  • Antibodies, Monoclonal
  • Costimulatory and Inhibitory T-Cell Receptors
  • Vascular Endothelial Growth Factor A
  • Asbestos

Supplementary concepts

  • Mesothelioma, Malignant